Drug Profile

BCN 057

Alternative Names: BCN-057

Latest Information Update: 28 Jul 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator University of California at Los Angeles
Developer BCN Biosciences
Class Small molecules
Mechanism of Action Apoptosis stimulants; Glycogen synthase kinase 3 beta inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Jul 2024 No recent reports of development identified for preclinical development in Radiation-injuries in USA (SC, Injection)
24 Jul 2020 BCN Bioscience signed agreement with the Biomedical Advanced Research and Development Authority (BARDA) for BCN 057, before June 2020
22 Jun 2020 BCN 057 licensed to BCN Bioscience, before June 2020

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com